Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Proof Suggested For DHEA Improving Pre-Menopausal Women's Sex Drive

"We've identified the patient population that would benefit from this," said Vitaly Kushnir, of  the Center for Human Reproduction. Fertility Nutraceuticals-backed study shows subjects' Female Sexual Function Index scores increased by 17% for desire, 12% for arousal and 8% for lubrication.

Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Dynavax has already received two complete response letters for its hepatitis B vaccine; more patients who received Heplisav died or experienced cardiovascular events compared with the competitor arm.

Keeping Track: Cardio, Antibiotic Approvals Put FDA Over Last Year's Novel Drug Count

The latest drug development news and US FDA highlights from our Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel